Efficacy of quadrivalent human papillomavirus vaccine (Gardasil) for recurrent respiratoru papillomatosis

Efficacy of quadrivalent human papillomavirus vaccine (Gardasil) for recurrent respiratoru papillomatosis - Quadrivalent human papillomavirus vaccine (Gardasil) for recurrent respiratoru papillomatosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020352

Enrollment

Registered

2015-12-25

Start date

2013-03-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent respiratory papillomatosis

Interventions

Vaccination with quadrivalent human papillomavirus vaccine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with recurrent respiratory papillomatosis who were resistant to previously received various treatments including laryngeal surgery

Exclusion criteria

Exclusion criteria: Patients with severe renal or liver dysfunction, with a risk for general anesthesia, or whom a doctor considered not eligible

Design outcomes

Primary

Measure	Time frame
Change of severity of recurrent respiratory papillomatosis based on Dearkay's severity score 3 months after completion of vaccination	—

Countries

Japan

Contacts

Public ContactYosuke Nakanishi

Kanazawa University Otolaryngology-Head and Neck Surgery

nakanish@med.kanazawa-u.ac.jp076-265-2413

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026